According to a new market report published by Lucintel, the future of the sepsis diagnostic market looks promising with opportunities in the hospitals, pathology, and reference laboratories. The sepsis diagnostic market is expected to grow with a CAGR of 9% from 2019 to 2024. The major growth drivers for this market are increasing geriatric population, development of drug-resistance among individuals, and high incidence of hospital acquired infection, and increasing number of surgical procedures.
Sepsis is a life-threatening condition caused by the response of host immune system to a bacterial infection. It causes injury to its own tissues and organs. In this market, microbiology, molecular diagnostics, immunoassay, flow cytometry, microfluidics, and biomarkers are the major technologies. Biomarker is expected to witness highest growth over the forecast period due to its various advantages in the diagnosis of sepsis and growing need for early disease diagnosis.
Within the sepsis diagnostic market, conventional diagnostic and automated diagnostic are the major methods. Automated diagnostic segment is expected to grow at the highest CAGR over forecast period.
North America will remain the largest region over the forecast period due to rise in geriatric population, infections that are incurable by antibiotics, growing adoption of advanced and new diagnostic techniques, and increasing incidences of chronic diseases.
Biomérieux, T2 Biosystems, Luminex, Becton, Dickinson (BD), Roche diagnostic, Danaher, Thermo Fisher Scientific, Bruker, Abbott, Immunexpress, Response Biomedical, Axis-Shield diagnostic, Cytosorbents, Mitsubishi Chemical, and EKF diagnostic are among the major manufacturers of sepsis diagnostic.
Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the sepsis diagnostic market by technology, product, pathogen, method, test type, end user, and region. Lucintel has prepared a comprehensive research report titled "Sepsis Diagnostic Market 2019-2024: Trends, Forecast, and Opportunity Analysis". The Lucintel report serves as a catalyst for growth strategy as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes a forecast for the sepsis diagnostic market by technology, product, pathogen, method, test type, end user, and region as follows:
By Technology [$M shipment analysis for 2013 – 2024]:
• Microbiology
• Molecular Diagnostic
• Immunoassays
• Flow Cytometry
• Microfluidics
• Biomarkers
By Product [$M shipment analysis for 2013 – 2024]:
• Blood Culture Media
• Assays & Reagents
• Instruments
• Software
By Pathogen [$M shipment analysis for 2013 – 2024]:
• Bacterial Sepsis
• Fungal Sepsis
• Other Pathogens
By Test Type [$M shipment analysis for 2013 – 2024]:
• Laboratory Tests
• Point-of-care Tests
By End User [$M shipment analysis for 2013 – 2024]:
• Hospitals
• Pathology & Reference Laboratories
By Region [$M shipment analysis for 2013 – 2024]:
• North America
• United States
• Canada
• Mexico
• Europe
• UK
• Germany
• Italy
• Asia Pacific
• China
• Japan
• India
• Rest of the World
This 150-page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link……. [email protected].
About Lucintel
Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.
This report addresses the following key questions:
Q.1. What are some of the most promising potential, high-growth opportunities for the sepsis diagnostics market by technology (microbiology, molecular diagnostics, immunoassays, flow cytometry, microfluidics, and biomarkers), product (blood culture media, assays & reagents, instruments, and software), pathogen (bacterial sepsis, fungal sepsis, and other pathogens), test type (laboratory tests and point-of-care tests), end user (hospitals and pathology & reference laboratories), and region (North America, Europe, Asia-Pacific, and ROW)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which regions will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the drivers and challenges of the sepsis diagnostics market?
Q.5. What are the business risks and threats to the sepsis diagnostics market?
Q.6. What are emerging trends in this sepsis diagnostics market and the reasons behind them?
Q.7. What are some changing demands of customers in the sepsis diagnostics market?
Q.8. What are the new developments in the sepsis diagnostics market? Which
companies are leading these developments?
Q.9. Who are the major players in this sepsis diagnostics market? What strategic initiatives are being implemented by key players for business growth?
Q.10. What are some of the competitive products and processes in this sepsis diagnostics area and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11. What M & A activities have taken place in the last 5 years in sepsis diagnostics market?